Teplizumab Production Cost Reports

The report provides a detailed analysis essential for establishing a Teplizumab production plant. It encompasses all critical aspects necessary for Teplizumab production, including the cost of Teplizumab production, Teplizumab plant cost, Teplizumab production costs, and the overall Teplizumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Teplizumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Teplizumab is an antibody medicine which calms overactive immune cells in the immune system. This stops the cells from mistakenly attacking and destroying the beta cells in the pancreas that make insulin, which is the main cause of type 1 diabetes. It is approved by the FDA for kids aged 8 and older and adults who are at high risk.

The full treatment is a 14-day course with increasing doses up to a total of 9 mg, and it works by keeping C-peptide levels steady. It is utilised in diabetes cases, kidney transplants, and skin conditions like psoriasis. Its common side effects include rash, low white blood cell count (lymphopenia or leukopenia), and headache. Other frequent effects include nausea, elevated liver enzymes, common cold-like symptoms, and diarrhoea.

The market for Teplizumab is influenced by the rising cases of type 1 diabetes. The strong demand for innovative disease-modifying therapies as the first approved to delay stage 3 onset in at-risk patients contributes to their market growth. The advances in early-stage diagnostics and ongoing R&D in autoimmune treatments further strengthen its market.

The high treatment costs are straining healthcare budgets, and reimbursement hurdles and formulary restrictions, plus requirements for speciality pharmacy distribution affects industrial Teplizumab procurement. Also, patient support programs that shape hospital and clinic sourcing decisions within reliable biologics supply chains further impact their sourcing.

Raw Material for Teplizumab Production

According to the Teplizumab production plant project report, the key raw materials used in the production of Teplizumab include Chinese hamster ovary (CHO) cells, cell culture media, and other salts.

Production Process of Teplizumab

The extensive Teplizumab production cost report consists of the following major industrial production process:

1. From Chinese hamster ovary (CHO) cells: The production process of Teplizumab uses Chinese hamster ovary (CHO) cells. The reaction takes place using a single-use production bioreactor for upstream processing. This is followed by downstream purification that includes affinity capture chromatography, low pH viral inactivation and neutralisation, anion exchange chromatography, nanofiltration, ultrafiltration and diafiltration. The Teplizumab is then thawed, pooled, sterile filtered, aseptically filled, inspected, and packaged as the final drug product.

Teplizumab is a monoclonal antibody with a molecular weight of around 150 kDa and a molecular formula of C6462H9938N1738O2022S46. It appears as a sterile, preservative-free, clear to opalescent, colourless aqueous solution at 1 mg/mL concentration. It has a pH of 6.1 (range 5.8–6.4), containing excipients like dibasic sodium phosphate, monobasic sodium phosphate, polysorbate, and sodium chloride in water for injection. Its central volume of distribution is 2.27 L in a 60 kg subject, with saturable clearance 2.7 L/day. It has a terminal half-life of 4.5 days and catabolism into small peptides. It is stable when refrigerated between 2–8 degree Celsius and is to be used within 4 hours at room temperature.